AzTrials
AzTrials

Cerebral Small Vessel DiseasesPhase 4NCT05578521

CerebrAlcare Pills on CereBral Small VesseL DiseasE(CABLE)

A Phase 4 study testing Cerebralcare pills in people with Cerebral Small Vessel Diseases, run by Beijing Tiantan Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is a randomized, double-blinded, placebo-controlled, multicenter trial. Cerebral small vessel disease (CSVD) patients will be diagnosed by Magnetic Resonance Imaging (MRI) and randomized into treatment or control groups. Read more about this study

Who is it for?
Ages 45 to 75 years
Conditions the study is for
Cerebral Small Vessel Diseases
What is being tested?
Cerebralcare pills
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
114 participants
Where
1 siteChina
Study dates
5 Jun 2022to 31 Mar 2024
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 45-75 years old;
  • No gender limitation;
  • Cerebral small vessel disease is observed on brain MRI. White matter hyperintensity, Fazekas score ≥ 1 and combined more than 2 vascular risk factors (hypertension, hyperlipidemia, diabetes, obesity, smoking, and other vascular events except stroke) or combined with lacunar focus or Imaging findings suggest new subcortical lacunar infarction (within 7 days).
  • Mild or moderate vascular cognitive impairment(16 ≤ MoCA ≤ 24 score, for patients with primary school degree or below,15 ≤ MoCA ≤ 23 score).
  • Daily life independence (mRS ≤ 2).
  • Sign informed consent.
Show all 9Show fewer
  • Note:
  • The imaging definition of small vessel disease refers to the strong guideline The total score of Fazekas was 6, which was the sum of Fazekas scores of subcortical and periventricular white matter lesions.
  • New subcortical lacunar infarction: head MRI examination, subcortical, basal ganglia or brain stem DWI showed high signal (ADC diffusion limited) lesions with diameter < 20 mm, with or without corresponding clinical symptoms; There were new clinical symptoms. FLAIR sequence of head MRI showed flair hyperintense lesions (diameter < 20 mm) in subcortical, basal ganglia or pons.

Who cannot join

  • Cerebral hemorrhage and subarachnoid hemorrhage occurred within 30 days.
  • Symptomatic middle cerebral artery and/or internal carotid artery stenosis, stenosis rate ≥ 50%; asymptomatic middle cerebral artery and/or internal carotid artery stenosis, stenosis rate ≥ 70%.
  • Coronary CTA or coronary angiography showed severe three vessel lesions or frequent angina pectoris within 30 days.
  • Chronic kidney disease stage 4 or 5.
  • Resistant hypertension which could not be controlled by medicine (SBP > 180mmHg or DBP > 110mmHg).
  • Resistant hyperglycemia which could not be controlled by medicine(fasting blood glucose > 10mmol/L or HB1AC > 7%).
Show all 24Show fewer
  • In acute cerebral infarction, the lesions showed high signal intensity on DWI, and the diameter was more than 20 mm or history of assive cerebral infarction within 30 days.
  • Neurodegenerative diseases, such as AD and PD, have been diagnosed.
  • There are clear non angiogenic white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy diseases, etc.
  • Untreated cerebrovascular malformations or intracranial aneurysms (d > 3mm).
  • Active gastrointestinal bleeding.
  • Coagulation dysfunction or history of systemic bleeding.
  • Hemorrhagic tendency (including but not limited to):PLT<100×109/L; heparin treatment within 48h; APTT ≥ 35s; current use of warfarin, INR > 1.7; current use of novel oral anticoagulants; current use of direct thrombin or factor Xa inhibitor.
  • Severe hepatic or renal or heat insufficiency before randomization (severe hepatic insufficiency refers to ALT or AST > 2 times the upper limit of normal; severe renal insufficiency refers to serum creatinine> 1.5 times the upper limit of normal or eGFR<40 ml/min/1.73m2; severe heat insufficiency refers to NYHA stage 3 and 4).
  • History of intracranial or intramedullary surgery within three months of randomization.
  • The patient has used or is using chinese medicine with similar components to CerebrAlcare pill/granule (including Tianshu capsule, Toutongning capsule, Naoxintong capsule, Danzhen Toutou capsule, Yindanxinnaotong soft capsule, Naoxinqing Tablet, Bazhen pill and Shiquandabu pill) within 14 days.
  • Definite indications for anticoagulation (suspicion of cardioembolism, e.g. atrial fibrillation, known heart valve prosthesis, atrial myxoma, endocarditis, etc.) or definite indications for dual antiplatelet therapy (e.g. recent coronary or cerebral artery stent implantation).
  • Other surgical or interventional therapy planned within 1 year requiring experimental drugs discontinuation.
  • Childbearing-age women who do not take effective methods of contraception without negative records of pregnancy tests.
  • Known to be allergic to CerebrAlcare pill/granule.
  • Contraindications of MRI examination (such as claustrophobia).
  • With severe organic diseases, such as malignant tumor, the expected survival time is less than 1 years.
  • Due to geographical or other reasons can not cooperate to complete the follow-up.
  • Patients also participated in other clinical trials.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Beijing Tiantan Hospital

    Beijing, 100070

Other trials in China

About this study

Official title: CerebrAlcare Pills on CereBral Small VesseL DiseasE(CABLE):A Randomized, Double-blinded, Placebo-controlled, Multi-center Trial

This is a randomized, double-blinded, placebo-controlled, multicenter trial. Cerebral small vessel disease (CSVD) patients will be diagnosed by Magnetic Resonance Imaging (MRI) and randomized into treatment or control groups. The purpose of this trial is to assess the efficacy of cerebralcare pills on cerebral small vessel disease.

Read the detailed description

Cerebral small vessel disease (CSVD) is prevalent in the aging population with insidious onset, almost affecting all levels of the brain vasculature, and challenges the social and healthcare system worldwide. CSVD is the major cause of 25% of strokes and more than doubles the odds of recurrent stroke; furthermore, it contributes to 45% of dementia cases and to global functional decline. However, an incomplete understanding of the pathogenesis of CSVD limits prevention and treatment efforts.

Cerebralcare Granule (CG) or Yangxue Qingnao granule, is a polyherbal medicine that was approved in 1997 by the China State Food and Drug Administration for the treatment of headaches and dizziness associated with cerebrovascular diseases. Cerebralcare pill is composed of 11 herbs. These herbs contain small molecules with various pharmacological actions. Cerebralcare pills have the same component as CG. Previous studies have demonstrated that CG significantly attenuated ischemia-reperfusion induced dysfunction, structural abnormalities in the microcirculation, and inflammatory injury. There are also studies confirming that CG also improved cognition function, improved cerebral microcirculation disorders, and hemodynamics.

Patients enrolled will be randomly assigned to either the treatment or control group to receive Brain Pill/Brain Pill placebo (from randomization to 6 months at a dose of 2 packs per day). Face-to-face interviews will be conducted at baseline, day 90, day 180, and 1 year after randomization.

The primary endpoint is the progression in cognition function which is assessed by Montreal Cognitive Assessment (MoCA) score. The secondary endpoints include changes in clinical characters, imaging markers (number and volume of white matter, number of lacunes, microbleeds, enlarged perivascular space ), hemodynamic parameters, Chinese medical symptoms, blood-brain barrier (BBB) permeability, proteomics, and inflammatory markers. The safety endpoints include severe hemorrhage events, symptomatic and asymptomatic intracranial hemorrhage, moderate hemorrhage, overall mortality, and serious adverse events.

Being tested
Cerebralcare pills, Cerebralcare pills placebo
Keywords
cerebral small vessel diseases, Cerebralcare Pills, cognitive function, randomized controlled trial, multicenter study, double blind study, placebo-controlled
Medical subject headings
Cerebral Small Vessel Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cerebralcare pillsDrug

    a dose of 2 packages, twice a day of Cerebralcare pills

  • Cerebralcare pills placeboDrug

    Cerebralcare pills placebo will be administrated at the same rate with experimental group

Study groups in NCT05578521
Study groupRoleWhat they receive
Cerebralcare pills placebo groupPlacebo comparatorThis group will receive Cerebralcare pills placebo, 2 packages, twice a day, from the day of randomization to 6 months.
Receives: Drug: Cerebralcare pills placebo
Cerebralcare pills groupExperimentalThis group will receive Cerebralcare pills, 2 packages, twice a day, from the day of randomization to 6 months.
Receives: Drug: Cerebralcare pills

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression in cognition function

    Cognition function assessed by Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome..

    Measured: 6 months after randomization

Secondary outcomes (23)
  1. Changes in both systolic and diastolic blood pressure

    Including systolic and diastolic blood pressure (mmHg).

    Measured: 3 months, 6 months and 1 year after randomization

  2. Rey auditory verbal learning test(RAVLT)

    The Rey Auditory Verbal Learning Test (RAVLT) provides a standardized procedure to evaluate a range of aspects of verbal learning and memory of supra-span lists of words. The test requires recalling as many words as possible in any order from a standard list of 15 unrelated words read out by the examiner. The total score ranges from 0-120, with a lower score indicating a worse outcome.

    Measured: 3 months, 6 months and 1 year after randomization

  3. Generalized Anxiety Disorder 7(GAD-7)

    Generalized Anxiety disorder (GAD) is a widespread psychiatric syndrome involving significant consequences on people's health, with a total score of 21, where a higher score means a worse outcome. However, recent data show that this disorder has received little attention when compared to other anxiety disorders.

    Measured: 3 months, 6 months and 1 year after randomization

  4. Self-rating depression scale

    The Zung Self-Rating Depression Scale (SDS) consists of 20 items with a Likert type scale after each item. Each item is rated from 1 to 4, with scores ranging from 20 to 80, where higher scores mean worse results

    Measured: 3 months, 6 months and 1 year after randomization

  5. Dizziness handicap inventory(DHI)

    The DHI has 25 items with 3 response levels, sub-grouped into three domains: functional, emotional, and physical. A shortened version, the Dizziness Handicap Inventory short form (DHIsf), reduced to 13 items with 2 response levels, has been shown to compare favourably to the original version. Scores range from 0-100, with higher scores indicating worse outcomes.

    Measured: 3 months, 6 months and 1 year after randomization

  6. Headache impact test 6(HIT-6)

    The HIT-6 consists of six items: pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress.Total HIT-6 score that ranges from 36 to 78, where a lower score indicates a greater impact of headache on the daily life of the respondent.

    Measured: 3 months, 6 months and 1 year after randomization

  7. EuroQol five dimensions questionnaire (EQ-5D)

    It includes a descriptive system(DS) and a visual analogue scale(VAS). Two indicators are index value(ranged 0-1) and visual score(ranged 0-100) with higher scores corresponding to better health status.

    Measured: 3 months, 6 months and 1 year after randomization

  8. Stroop Color Word Test

    The Stroop Color and Word Test (SCWT) is a neuropsychological test extensively used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect. Shorter the test time, the better the outcome.

    Measured: 3 months, 6 months and 1 year after randomization

  9. Severity of white matter hyperintensities(WMHs)

    Fazekas score is used to describe the different types of hyperintense signal abnormalities surrounding the ventricles and in the deep white matter. Periventricular hyperintensity (PVH) is graded as 0 = absence, 1 = "caps" or pencil-thin lining, 2 = smooth "halo", 3 = irregular PVH extending into the deep white matter. Separate deep white matter hyperintensity (DWMH) is rated as 0 = absence, 1 = punctate foci, 2 = beginning confluence of foci, 3 = large confluent areas. Higher scores indicats a worse outcome.

    Measured: 6 months and 1 year after randomization

  10. Changes of white matter hyperintensities(WMHs) volume

    WMH volume is assessed on 3D fluid attenuated inversion recovery (FLAIR) sequence in mm3 or cm3. Larger volume indicates a worse outcome.

    Measured: 6 months and 1 year after randomization

  11. Number of lacunes

    Lacunes were defined as rounded or ovoid lesions in the subcortical, basal ganglia, or brainstem, ranging from 3mm to 20mm in diameter, presenting with cerebral spinal fluid signal intensity on T2 and FLAIR, generally featuring a hyperintense rim on FLAIR and no increased signal on diffusion weighted imaging (DWI). Higher number of lacunae means a worse outcome.

    Measured: 6 months and 1 year after randomization

  12. Number of cerebral microbleeds

    Cerebral microbleeds are defined as rounded, hypodense foci within brain parenchyma on susceptibi lity weighted imaging (SWI) sequence, up to 10 mm in diameter, and were differentiated from microbleed mimics based on current guidelines. Higher number of cerebral microbleeds means a worse outcome.

    Measured: 6 months and 1 year after randomization

  13. Number of enlarged perivascular space

    Enlarged perivascular space was defined as small punctate or linear hyperintensities on T2 images in the basal ganglia or centrum semiovale. Higher number of enlarged perivascular spaces means a worse outcome.

    Measured: 6 months and 1 year after randomization

  14. Changes in hemodynamic parameters

    Lower cerebrovascular reactivity (CVR), cerebral blood flow (CBF), and reduced radial peripapillary capillary network density, and parafoveal vessel densities of the superficial retinal capillary plexuses mean worse outcomes.

    Measured: 6 months and 1 year after randomization

  15. changes in Chinese medical symptoms

    Chinese medical symptoms assessed by Blood Deficiency and Liver Hyperactivity Syndrome score. Scores range 0-21 and higher scores mean a worse outcome.

    Measured: 6 months and 1 year after randomization

  16. Difference of recurrent stroke between groups

    stroke included ischemic stroke, hemorrhagic stroke, TIA, et al.

    Measured: 3 months, 6 months and 1 year after randomization

  17. changes in Blood-Brain Barrier (BBB) Permeability between groups

    BBB permeability is assessed by MRI and biomarker (including NSE, GFAP, S100β).

    Measured: 6 months and 1 year after randomization

  18. Compare protein profiles observed among different groups.

    Blood was collected from the healthy (n=6), experimental (n=6) and placebo (n=6) groups at baseline, 3 months, and 12 months post-dosing. Alterations in protein profiles were detected by high performance liquid chromatography-mass spectrometry (HPLC-MS). GO classification and pathway enrichment were performed to analyse relevant protein changes. Serum metabolomics was determined using untargeted assays, and metabolite patterns in different groups were distinguished using orthogonal partial least squares analysis (OPLS-DA), compared with databases, and validated with the help of standards to finalise qualitative and quantitative analysis of metabolites and to identify differential metabolites. The Cell Counting Bead Analysis (CBA) Flex Set Flow Multifactor Assay Kit is used to detect serum levels of the inflammatory factors IL-1β, IL-6, IL-10, IL-12 and TNF-α. Western blot analysis is used to validate changes in the expression of 20 key proteins obtained from proteomic analysis.

    Measured: 6 months and 1 year after randomization

  19. Composite vascular events

    Incidence of symptomatic stroke, myocardial infarction and vascular death.

    Measured: 3 months, 6 months and 1 year after randomization

  20. All-cause death

    Deaths from all causes to the research subjects

    Measured: 3 months, 6 months and 1 year after randomization

  21. Moderate and/or severe hemorrhage events

    According to Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) criteria which classifies the severity of bleeding complications as follows: 1) severe or life-threatening bleeding-intracranial bleeding or bleeding that causes substantial hemodynamic compromise requiring treatment; 2) moderate bleeding-bleeding which needs blood transfusion; 3) minor bleeding-other bleeding, neither requiring transfusion nor causing hemodynamic compromise.

    Measured: 3 months, 6 months and 1 year after randomization

  22. Symptomatic and/or asymptomatic intracranial hemorrhage

    Measured: 3 months, 6 months and 1 year after randomization

  23. Adverse events and severe adverse events

    renal failure, hepatic failure, death.

    Measured: 3 months, 6 months and 1 year after randomization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Oct 2022
  2. Study start5 Jun 2022
  3. Primary completion31 Dec 2023 (estimated)
  4. Study completion31 Mar 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
114 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05578521
Sponsor's protocol ID
KY-2021-176-04
Status last verified
Oct 2022
First submitted
24 Jul 2022
Last updated
13 Oct 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Zhou M, Gong Y, Han S, Wang M, Gu W, Chen HS, Zheng W, Feng K, Wang D, Li H, Zheng Z, Pan Y, Chen W, Wang Y. CerebrAlcare Pills on CereBral Small VesseL DiseasE (CABLE) trial: rationale and design. Stroke Vasc Neurol. 2026 Apr 27;11(2):247-252. doi: 10.1136/svn-2024-003756.

    PubMed 40897453

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Cerebralcare pills in people with Cerebral Small Vessel Diseases, run by Beijing Tiantan Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression in cognition function (time frame: 6 months after randomization). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05578521, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in